La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Hebei Changshan Biochemical Pharmaceutical Bilan de santé
Santé financière contrôle des critères 2/6
Hebei Changshan Biochemical Pharmaceutical has a total shareholder equity of CN¥1.7B and total debt of CN¥2.0B, which brings its debt-to-equity ratio to 117.1%. Its total assets and total liabilities are CN¥4.7B and CN¥2.9B respectively.
Informations clés
117.1%
Ratio d'endettement
CN¥2.03b
Dette
Ratio de couverture des intérêts | n/a |
Argent liquide | CN¥321.99m |
Fonds propres | CN¥1.74b |
Total du passif | CN¥2.93b |
Total des actifs | CN¥4.67b |
Mises à jour récentes de la santé financière
Recent updates
Pinning Down Hebei Changshan Biochemical Pharmaceutical Co., Ltd.'s (SZSE:300255) P/S Is Difficult Right Now
Jul 25Is Hebei Changshan Biochemical Pharmaceutical (SZSE:300255) Using Too Much Debt?
May 27Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SZSE:300255) May Have Run Too Fast Too Soon With Recent 25% Price Plummet
Apr 15Hebei Changshan Biochemical Pharmaceutical Co., Ltd.'s (SZSE:300255) 30% Share Price Surge Not Quite Adding Up
Mar 01Analyse de la situation financière
Passif à court terme: 300255's short term assets (CN¥2.3B) exceed its short term liabilities (CN¥1.9B).
Passif à long terme: 300255's short term assets (CN¥2.3B) exceed its long term liabilities (CN¥993.8M).
Historique et analyse du ratio d'endettement
Niveau d'endettement: 300255's net debt to equity ratio (98.6%) is considered high.
Réduire la dette: 300255's debt to equity ratio has increased from 34.8% to 117.1% over the past 5 years.
Couverture de la dette: 300255's debt is not well covered by operating cash flow (12.2%).
Couverture des intérêts: Insufficient data to determine if 300255's interest payments on its debt are well covered by EBIT.